HRP20211544T1 - Postupci za unapređivanje odgovora t stanica - Google Patents
Postupci za unapređivanje odgovora t stanica Download PDFInfo
- Publication number
- HRP20211544T1 HRP20211544T1 HRP20211544TT HRP20211544T HRP20211544T1 HR P20211544 T1 HRP20211544 T1 HR P20211544T1 HR P20211544T T HRP20211544T T HR P20211544TT HR P20211544 T HRP20211544 T HR P20211544T HR P20211544 T1 HRP20211544 T1 HR P20211544T1
- Authority
- HR
- Croatia
- Prior art keywords
- cancer
- antagonist
- use according
- agent
- human
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title 1
- 230000001737 promoting effect Effects 0.000 title 1
- 239000005557 antagonist Substances 0.000 claims 17
- 101000942282 Homo sapiens C-type lectin domain family 1 member A Proteins 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 108091023037 Aptamer Proteins 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000032271 Malignant tumor of penis Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000002471 Penile Neoplasms Diseases 0.000 claims 1
- 206010034299 Penile cancer Diseases 0.000 claims 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 1
- 208000007452 Plasmacytoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 201000000582 Retinoblastoma Diseases 0.000 claims 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims 1
- 206010061934 Salivary gland cancer Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 230000005867 T cell response Effects 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 230000033228 biological regulation Effects 0.000 claims 1
- 201000000220 brain stem cancer Diseases 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 210000003026 hypopharynx Anatomy 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 210000003928 nasal cavity Anatomy 0.000 claims 1
- 238000011275 oncology therapy Methods 0.000 claims 1
- 210000003300 oropharynx Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 210000003695 paranasal sinus Anatomy 0.000 claims 1
- 201000002511 pituitary cancer Diseases 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 230000022983 regulation of cell cycle Effects 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 210000001541 thymus gland Anatomy 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 206010046885 vaginal cancer Diseases 0.000 claims 1
- 208000013139 vaginal neoplasm Diseases 0.000 claims 1
- 201000005102 vulva cancer Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4726—Lectins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1732—Lectins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/7056—Lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Marine Sciences & Fisheries (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Claims (13)
1. Antagonist humanog CLEC-1 za uporabu u liječenju humanog subjekta koji boluje od raka.
2. Antagonist za uporabu prema patentnom zahtjevu 1, naznačen time što humani subjekt boluje od raka koji je odabran iz grupe koja se sastoji od raka žučnih kanala, raka mjehura, raka kostiju, raka mozga i centralnog živčanog sustava, raka dojke, Castlemanove bolesti raka vrata maternice, kolorektalnog raka, raka endometrija, raka jednjaka, raka žučnog mjehura, gastrointestinalnih karcinoidnih tumora, Hodkinove bolesti, ne-Hodkinovog limfoma, Kaposijevog sarkoma, raka bubrega, raka larinksa i hipofarinksa, raka jetre, raka pluća, mezotelioma, plazmacitoma, raka nosne šupljine i paranazalnih sinusa, raka nazofarinksa, neuroblastoma, raka usne šupljine i orofarinksa, raka jajnika, raka gušterače, raka penisa, raka hipofize, raka prostate, retinoblastoma, rabdomiosarkoma, raka žlijezda slinovnica, raka kože, raka želuca, raka testisa, rak timusa, raka štitnjače, raka vagine, raka vulve i raka maternice.
3. Antagonist za uporabu prema patentnom zahtjevu 1 ili 2, naznačen time što je antagonist humanog CLEC-1 antitijelo ili njegov antigen-vezujući fragment.
4. Antagonist za uporabu prema patentnom zahtjevu 3, naznačen time što je antagonist humanog CLEC-1 odabran iz grupe koja se sastoji od himernih antitijela, humaniziranih ili potpuno humanih monoklonskih antitijela, ili njihovih antigen-vezujućih fragmenata.
5. Antagonist za uporabu prema patentnom zahtjevu 3 ili 4, naznačen time što se antitijelo ili njegov antigen-vezujući fragment specifično veže za ekstracelularnu domenu humanog CLEC-1.
6. Antagonist za uporabu prema patentnom zahtjevu 1 ili 2, naznačen time što je antagonist humanog CLEC-1 polipeptid.
7. Antagonist za uporabu prema patentnom zahtjevu 6, naznačen time što je polipeptid funkcionalni ekvivalent humanog CLEC-1.
8. Antagonist za uporabu prema patentnom zahtjevu 7, naznačen time što je polipeptid funkcionalni ekvivalent humanog CLEC-1 spojen sa konstantnom domenom imunoglobulina.
9. Antagonist za uporabu prema patentnom zahtjevu 1 ili 2, naznačen time što je antagonist humanog CLEC-1 aptamer.
10. Antagonist za uporabu prema bilo kojem od patentnih zahtjeva 1 do 9, naznačen time što se rak liječi tako što se unapređuje odgovor T stanica.
11. Antagonist za uporabu prema bilo kojem od patentnih zahtjeva 1 do 10, u kombinaciji sa konvencionalnim tretmanom za rak.
12. Antagonist za uporabu prema bilo kojem od patentnih zahtjeva 1 do 11, u kombinaciji sa sredstvom izabranim od kemoterapeutskog sredstva, ciljane terapije za rak, imunoterapeutskog sredstva ili radioterapije, naročito za istovremenu, odvojenu ili uzastopnu primjenu.
13. Antagonist za uporabu prema patentnom zahtjevu 12, naznačen time što je sredstvo odabrano iz grupe koja se sastoji od citotoksičnog sredstva, antiangiogenog sredstva, imunogenskog sredstva protiv raka, sredstva za regulaciju kontrole staničnog ciklusa/apoptoze, antitijela protiv raka i sredstva za regulaciju hormona.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16306381 | 2016-10-21 | ||
| EP17305988 | 2017-07-24 | ||
| EP17797066.2A EP3529262B1 (en) | 2016-10-21 | 2017-10-20 | Methods for promoting t cells response |
| PCT/EP2017/076911 WO2018073440A1 (en) | 2016-10-21 | 2017-10-20 | Methods for promoting t cells response |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211544T1 true HRP20211544T1 (hr) | 2022-01-07 |
Family
ID=60293924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211544TT HRP20211544T1 (hr) | 2016-10-21 | 2017-10-20 | Postupci za unapređivanje odgovora t stanica |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11365257B2 (hr) |
| EP (2) | EP3950709B1 (hr) |
| JP (2) | JP7032396B6 (hr) |
| KR (1) | KR102646708B1 (hr) |
| CN (1) | CN110291102A (hr) |
| AU (1) | AU2017345286B2 (hr) |
| CA (1) | CA3039348C (hr) |
| CY (1) | CY1124584T1 (hr) |
| DK (1) | DK3529262T3 (hr) |
| ES (1) | ES2883678T3 (hr) |
| HR (1) | HRP20211544T1 (hr) |
| HU (1) | HUE056016T2 (hr) |
| IL (1) | IL266111B (hr) |
| LT (1) | LT3529262T (hr) |
| MA (1) | MA46570B1 (hr) |
| MD (1) | MD3529262T2 (hr) |
| PL (1) | PL3529262T3 (hr) |
| RS (1) | RS62463B1 (hr) |
| SI (1) | SI3529262T1 (hr) |
| WO (1) | WO2018073440A1 (hr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3950709B1 (en) * | 2016-10-21 | 2024-02-14 | OSE Immunotherapeutics | Methods for promoting t cells response |
| KR20190141657A (ko) | 2017-02-28 | 2019-12-24 | 보르 바이오파마, 인크. | 계통 특이적 단백질의 억제를 위한 조성물 및 방법 |
| KR20220036908A (ko) | 2018-08-28 | 2022-03-23 | 보르 바이오파마 인크. | 유전자 조작된 조혈 줄기 세포 및 그의 용도 |
| JP2023504733A (ja) | 2019-12-05 | 2023-02-06 | オーエスイー・イミュノセラピューティクス | 抗ｃｌｅｃ－１ａ抗体及びその抗原結合性断片 |
| EP4352097A1 (en) | 2021-06-08 | 2024-04-17 | Ose Immunotherapeutics | Humanized anti-clec-1a antibodies and antigen-binding fragments thereof and mimetics thereof |
| WO2023083890A1 (en) * | 2021-11-09 | 2023-05-19 | Ose Immunotherapeutics | Identification of clec-1 ligand and uses thereof |
| WO2024028347A1 (en) | 2022-08-01 | 2024-02-08 | Ose Immunotherapeutics | Heterodimeric fc-clec-1 fusion molecule and uses thereof |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| DK1589107T3 (da) | 1992-08-21 | 2010-04-26 | Univ Bruxelles | Immonuglobuliner uden lette kæder |
| US5618829A (en) | 1993-01-28 | 1997-04-08 | Mitsubishi Chemical Corporation | Tyrosine kinase inhibitors and benzoylacrylamide derivatives |
| WO1995002420A2 (en) | 1993-07-15 | 1995-01-26 | Cancer Research Campaign Technology Ltd. | Prodrugs of protein tyrosine kinase inhibitors |
| EP0690452A3 (en) | 1994-06-28 | 1999-01-07 | Advanced Micro Devices, Inc. | Electrically erasable memory and method of erasure |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| US5639757A (en) | 1995-05-23 | 1997-06-17 | Pfizer Inc. | 4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors |
| CA2249446C (en) | 1996-04-12 | 2008-06-17 | Warner-Lambert Company | Irreversible inhibitors of tyrosine kinases |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| US6100254A (en) | 1997-10-10 | 2000-08-08 | Board Of Regents, The University Of Texas System | Inhibitors of protein tyrosine kinases |
| US6740665B1 (en) | 1999-02-10 | 2004-05-25 | Ramachandran Murali | Tyrosine kinase inhibitors and methods of using the same |
| US6245759B1 (en) | 1999-03-11 | 2001-06-12 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| AU5636900A (en) | 1999-06-30 | 2001-01-31 | Merck & Co., Inc. | Src kinase inhibitor compounds |
| WO2001000207A1 (en) | 1999-06-30 | 2001-01-04 | Merck & Co., Inc. | Src kinase inhibitor compounds |
| US6316444B1 (en) | 1999-06-30 | 2001-11-13 | Merck & Co., Inc. | SRC kinase inhibitor compounds |
| ES2250186T3 (es) | 1999-09-10 | 2006-04-16 | MERCK & CO., INC. | Inhibidores de tirosina quinasa. |
| ES2235970T3 (es) | 1999-10-19 | 2005-07-16 | MERCK & CO. INC. | Inhibidores de tirosina quinasa. |
| US6794393B1 (en) | 1999-10-19 | 2004-09-21 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| CA2387351C (en) | 1999-10-19 | 2009-09-08 | Merck & Co., Inc. | Indole derivatives as tyrosine kinase inhibitors |
| CN1454215B (zh) * | 1999-11-15 | 2013-01-02 | 米勒腾尼生物技术有限公司 | 树突状细胞特异的抗原结合片段、组合物及其使用方法、被其识别的抗原及由其获得的细胞 |
| US6313138B1 (en) | 2000-02-25 | 2001-11-06 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US6420382B2 (en) | 2000-02-25 | 2002-07-16 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| ES2255621T3 (es) | 2001-06-22 | 2006-07-01 | MERCK & CO., INC. | Inhibidores de tirosina quinasa. |
| US6958340B2 (en) | 2001-08-01 | 2005-10-25 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US6927293B2 (en) | 2001-08-30 | 2005-08-09 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US8246959B1 (en) | 2003-08-01 | 2012-08-21 | University Of Washington | Dendritic cell-associated lectin-like molecules, compositions and methods of use |
| US7908091B2 (en) | 2006-03-17 | 2011-03-15 | Prometheus Laboratories Inc. | Methods of predicting and monitoring tyrosine kinase inhibitor therapy |
| NZ595319A (en) * | 2007-02-23 | 2012-09-28 | Baylor Res Inst | Activation of human antigen-presenting cells through clec-6 |
| US20130058957A1 (en) * | 2010-02-23 | 2013-03-07 | The University Of Tokyo | Dendritic cell immunoreceptor agonist |
| RU2741120C2 (ru) * | 2014-07-21 | 2021-01-22 | Новартис Аг | Лечение рака с использованием химерного антигенного рецептора cll-1 |
| EP3950709B1 (en) * | 2016-10-21 | 2024-02-14 | OSE Immunotherapeutics | Methods for promoting t cells response |
-
2017
- 2017-10-20 EP EP21178847.6A patent/EP3950709B1/en active Active
- 2017-10-20 HU HUE17797066A patent/HUE056016T2/hu unknown
- 2017-10-20 WO PCT/EP2017/076911 patent/WO2018073440A1/en active Application Filing
- 2017-10-20 CA CA3039348A patent/CA3039348C/en active Active
- 2017-10-20 HR HRP20211544TT patent/HRP20211544T1/hr unknown
- 2017-10-20 LT LTEPPCT/EP2017/076911T patent/LT3529262T/lt unknown
- 2017-10-20 MD MDE20190953T patent/MD3529262T2/ro unknown
- 2017-10-20 KR KR1020197014209A patent/KR102646708B1/ko active IP Right Grant
- 2017-10-20 RS RS20211221A patent/RS62463B1/sr unknown
- 2017-10-20 CN CN201780065072.6A patent/CN110291102A/zh active Pending
- 2017-10-20 DK DK17797066.2T patent/DK3529262T3/da active
- 2017-10-20 PL PL17797066T patent/PL3529262T3/pl unknown
- 2017-10-20 SI SI201730876T patent/SI3529262T1/sl unknown
- 2017-10-20 US US16/343,757 patent/US11365257B2/en active Active
- 2017-10-20 MA MA46570A patent/MA46570B1/fr unknown
- 2017-10-20 IL IL266111A patent/IL266111B/en unknown
- 2017-10-20 AU AU2017345286A patent/AU2017345286B2/en active Active
- 2017-10-20 EP EP17797066.2A patent/EP3529262B1/en active Active
- 2017-10-20 JP JP2019521034A patent/JP7032396B6/ja active Active
- 2017-10-20 ES ES17797066T patent/ES2883678T3/es active Active
-
2021
- 2021-09-24 CY CY20211100839T patent/CY1124584T1/el unknown
-
2022
- 2022-02-22 JP JP2022025697A patent/JP7404418B6/ja active Active
- 2022-05-10 US US17/740,849 patent/US20220281983A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211544T1 (hr) | Postupci za unapređivanje odgovora t stanica | |
| JP2022065159A5 (hr) | ||
| HRP20210977T1 (hr) | Ciljano inhibiranje tgf beta | |
| HRP20192347T1 (hr) | Antitijela prema klaudinu 18.2 koja su korisna u dijagnozi tumora | |
| HRP20170834T1 (hr) | Antitijela protiv erbb3 i njihove uporabe | |
| HRP20192098T1 (hr) | Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene | |
| JP2010163438A5 (hr) | ||
| BR112019010356A2 (pt) | molécula de carboidrato, conjugado fármaco-anticorpo (adc), composição, método para preparar a composição, método para tratar câncer em um indivíduo, método para induzir ou melhorar a reação imune em um indivíduo necessitando do mesmo, composto conjugado de fármaco-anticorpo, uso de um composto conjungado anticorpo-fáramco, método para determinar a eficácia terapêutica de células de câncer ao adcc e método para fazer imagem de um indivíduo | |
| MX2013011363A (es) | Anticuerpos para peptidos citosolicos. | |
| JP2020503252A5 (hr) | ||
| JP2018027952A5 (hr) | ||
| WO2016191246A3 (en) | T cell receptor-like antibodies specific for a prame peptide | |
| HRP20160212T1 (hr) | Antitijela za terapiju kancera koji eksprimira klaudin 6 | |
| HRP20221088T1 (hr) | Protutijela i postupci uporabe | |
| MX2010002053A (es) | Composiciones de proteinas de fusion de notch humanizadas y metodos de tratamiento. | |
| HRP20200034T1 (hr) | Monoklonska protutijela protiv čimbenika rasta i diferencijacije 15 (gdf-15), te njihova upotreba u liječenju kaheksije uzrokovane rakom i raka | |
| MX2021015888A (es) | Fusión de un anticuerpo que se une a cea y 4-1bbl. | |
| JP2014527814A5 (hr) | ||
| JP2018052979A5 (hr) | ||
| RU2018100424A (ru) | Комбинированная терапия для лечения злокачественной опухоли | |
| RU2014101669A (ru) | Агенты, связывающие белки r-спондины (rspo), и способы их применения | |
| JP2016521692A5 (hr) | ||
| CO6612253A2 (es) | Agentas y antagonistas fijadores de notch y metodos para el uso de los mismos | |
| AR086693A1 (es) | PROTEINAS HUMANAS DE UNION AL ANTIGENO QUE SE UNEN A UN COMPLEJO QUE COMPRENDE b-KLOTHO Y UN RECEPTOR PARA FGF | |
| WO2016033284A4 (en) | Combination therapy for treatment of cancer |